---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-018402"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:50:20.367277+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alkermes reports FY2024 revenue $1.56B, net income $372M; guides FY2025 rev $1.34-$1.43B

## Summary
- FY2024 total revenues $1.56B, proprietary net sales up 18% YoY to $1.08B; GAAP diluted EPS from cont. ops $2.20.
- Q4 proprietary net sales $307.7M: LYBALVI $77M (+37%), ARISTADA $96.6M (+16%), VIVITROL $134.1M (+31%).
- Year-end cash/investments $824.8M; debt-free after retiring $290M debt; repurchased $200M shares in 2024.
- FY2025 guidance: rev $1.34-$1.43B, GAAP net income $175-$205M, R&D spend up to $335M for pipeline.
- ALKS 2680 Phase 2 narcolepsy data expected H2 2025; Phase 2 in idiopathic hypersomnia planned; ALKS 4510/7290 Phase 1 starts.

## SEC filing metadata
- accession: 0000950170-25-018402
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017025018402/0000950170-25-018402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017025018402/alks-20250212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-018402
- JSON: https://secwatch.observer/filing/0000950170-25-018402.json
- Plain text: https://secwatch.observer/filing/0000950170-25-018402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.